Alex W Tong

Summary

Affiliation: Baylor University Medical Center
Country: USA

Publications

  1. pmc A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors
    John Nemunaitis
    Mary Crowley Cancer Research Centers, Dallas, Texas, USA
    Mol Ther 18:429-34. 2010
  2. ncbi request reprint Prospects for CD40-directed experimental therapy of human cancer
    Alex W Tong
    Cancer Immunology Research Laboratory, Baylor Sammons Cancer Center, Baylor University Medical Center, Dallas, Texas 75246, USA
    Cancer Gene Ther 10:1-13. 2003
  3. doi request reprint MicroRNA profile analysis of human prostate cancers
    A W Tong
    Gradalis, Inc, Dallas, TX, USA
    Cancer Gene Ther 16:206-16. 2009
  4. ncbi request reprint Small RNAs and non-small cell lung cancer
    Alex W Tong
    Cancer Immunology Research Laboratory, Baylor Sammons Cancer Center, 3500 Gaston Avenue, Dallas, TX 75246, USA
    Curr Mol Med 6:339-49. 2006
  5. ncbi request reprint Small interfering RNA for experimental cancer therapy
    Alex W Tong
    Baylor University Medical Center, Baylor Sammons Cancer Center, Mary Crowley Medical Research Center, Research Laboratory, 3500 Gaston Avenue, Dallas, TX 75246, USA
    Curr Opin Mol Ther 7:114-24. 2005
  6. pmc Hereditary inclusion body myopathy: single patient response to intravenous dosing of GNE gene lipoplex
    Gregory Nemunaitis
    Mary Crowley Cancer Research Centers, Dallas, TX 75201, USA
    Hum Gene Ther 22:1331-41. 2011
  7. doi request reprint Antitumor activity of an oncolytic adenoviral-CD40 ligand (CD154) transgene construct in human breast cancer cells
    Erica M Gomes
    Cancer Immunology Research Laboratory and Department of Pathology, Baylor Sammons Cancer Center, Dallas, TX 75246, USA
    Clin Cancer Res 15:1317-25. 2009
  8. ncbi request reprint Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients
    John Nemunaitis
    US Oncology, Dallas, Texas 75246, USA
    Cancer Gene Ther 10:341-52. 2003
  9. doi request reprint In vivo safety and antitumor efficacy of bifunctional small hairpin RNAs specific for the human Stathmin 1 oncoprotein
    Anagha P Phadke
    Gradalis, Inc, Dallas, TX 75201, USA
    DNA Cell Biol 30:715-26. 2011
  10. ncbi request reprint Growth inhibition of human multiple myeloma cells by an oncolytic adenovirus carrying the CD40 ligand transgene
    Margret S Fernandes
    Cancer Immunology Research Laboratory, Baylor Sammons Cancer Center, Baylor University Medical Center, Dallas, TX 75246, USA
    Clin Cancer Res 15:4847-56. 2009

Research Grants

  1. Oncolytic Viral Delivery of Oncogene siRNA
    Alex Tong; Fiscal Year: 2006

Collaborators

Detail Information

Publications17

  1. pmc A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors
    John Nemunaitis
    Mary Crowley Cancer Research Centers, Dallas, Texas, USA
    Mol Ther 18:429-34. 2010
    ..Seven patients fulfilled Response Evaluation Criteria in Solid Tumors (RECIST) definition for stable disease at day 56 after treatment. Telomelysin was well tolerated. Evidence of antitumor activity was suggested...
  2. ncbi request reprint Prospects for CD40-directed experimental therapy of human cancer
    Alex W Tong
    Cancer Immunology Research Laboratory, Baylor Sammons Cancer Center, Baylor University Medical Center, Dallas, Texas 75246, USA
    Cancer Gene Ther 10:1-13. 2003
    ..This review summarizes recent findings on CD154 recombinant protein- and gene therapy-based tumor treatment approaches, and examines our understanding of the multifaceted molecular mechanisms of CD154-CD40 interactions...
  3. doi request reprint MicroRNA profile analysis of human prostate cancers
    A W Tong
    Gradalis, Inc, Dallas, TX, USA
    Cancer Gene Ther 16:206-16. 2009
    ..Growth inhibition through the reconstitution of miRNAs is potentially applicable for experimental therapy of prostate cancer, pending molecular validation of targeted genes...
  4. ncbi request reprint Small RNAs and non-small cell lung cancer
    Alex W Tong
    Cancer Immunology Research Laboratory, Baylor Sammons Cancer Center, 3500 Gaston Avenue, Dallas, TX 75246, USA
    Curr Mol Med 6:339-49. 2006
    ....
  5. ncbi request reprint Small interfering RNA for experimental cancer therapy
    Alex W Tong
    Baylor University Medical Center, Baylor Sammons Cancer Center, Mary Crowley Medical Research Center, Research Laboratory, 3500 Gaston Avenue, Dallas, TX 75246, USA
    Curr Opin Mol Ther 7:114-24. 2005
    ....
  6. pmc Hereditary inclusion body myopathy: single patient response to intravenous dosing of GNE gene lipoplex
    Gregory Nemunaitis
    Mary Crowley Cancer Research Centers, Dallas, TX 75201, USA
    Hum Gene Ther 22:1331-41. 2011
    ..Further assessment will involve a phase I trial of intravenous administration of GNE gene lipoplex in individuals with less advanced HIBM with more muscle function...
  7. doi request reprint Antitumor activity of an oncolytic adenoviral-CD40 ligand (CD154) transgene construct in human breast cancer cells
    Erica M Gomes
    Cancer Immunology Research Laboratory and Department of Pathology, Baylor Sammons Cancer Center, Dallas, TX 75246, USA
    Clin Cancer Res 15:1317-25. 2009
    ..In this proof-of-principle study, we examined the breast cancer growth-regulatory activities of an oncolytic adenoviral construct carrying the CD40L transgene (AdEHCD40L)...
  8. ncbi request reprint Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients
    John Nemunaitis
    US Oncology, Dallas, Texas 75246, USA
    Cancer Gene Ther 10:341-52. 2003
    ..Further investigation of ONYX-015, possibly with agents that may modulate replication activity, or duration of virus survival, is indicated...
  9. doi request reprint In vivo safety and antitumor efficacy of bifunctional small hairpin RNAs specific for the human Stathmin 1 oncoprotein
    Anagha P Phadke
    Gradalis, Inc, Dallas, TX 75201, USA
    DNA Cell Biol 30:715-26. 2011
    ..5 μg; HED of <0.09 mg/kg) confirmed systemic safety of the therapeutic dose, hence supporting early-phase assessments of clinical safety and preliminary efficacy...
  10. ncbi request reprint Growth inhibition of human multiple myeloma cells by an oncolytic adenovirus carrying the CD40 ligand transgene
    Margret S Fernandes
    Cancer Immunology Research Laboratory, Baylor Sammons Cancer Center, Baylor University Medical Center, Dallas, TX 75246, USA
    Clin Cancer Res 15:4847-56. 2009
    ..The growth-inhibitory activity of recombinant CD40 ligand (CD40L) is well documented in human multiple myeloma (MM). We examined MM-targeted delivery of CD40L by a conditional replicative oncolytic adenovirus, AdEHCD40L...
  11. ncbi request reprint Systemic therapeutic gene delivery for cancer: crafting Paris' arrow
    Alex W Tong
    Gradalis, Inc, Dallas, TX 75246, USA
    Curr Gene Ther 9:45-60. 2009
    ..Improvements in each of these respective areas of study have converged to yield promising in vivo results...
  12. ncbi request reprint miRNA profiling for diagnosis and prognosis of human cancer
    Chris Jay
    Murex Pharmaceuticals, Dallas, Texas, USA
    DNA Cell Biol 26:293-300. 2007
    ..The evaluation of miRNAs expression may also be of prognostic value, as best exemplified by the correlation of let-7 and mir-155 levels with disease survival in nonsmall cell lung cancer...
  13. ncbi request reprint Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients
    Alex W Tong
    Baylor Sammons Cancer Center, Baylor University Medical Center, Dallas, TX 75246, USA
    Mol Ther 11:160-72. 2005
    ..Intratumoral delivery of INGN 241 induced apoptosis in a large volume of tumor and elicited tumor-regulatory and immune-activating events that are consistent with the preclinical features of MDA-7/IL-24...
  14. doi request reprint Hereditary inclusion body myopathy: single patient response to GNE gene Lipoplex therapy
    Gregory Nemunaitis
    Mary Crowley Cancer Research Centers, 1700 Pacific, Dallas, TX 75201, USA
    J Gene Med 12:403-12. 2010
    ..Afflicted patients have no therapeutic options. In preclinical testing, we have previously demonstrated the ability to correct GNE gene function and the safety of delivery of wild type GNE gene using a liposomal delivery vehicle...
  15. ncbi request reprint Oncolytic viruses for induction of anti-tumor immunity
    Alex W Tong
    Gradalis, Inc Dallas, TX, USA
    Curr Pharm Biotechnol 13:1750-60. 2012
    ..We discuss the innate and adaptive immune activating events that may contribute to these clinical outcomes, and examine systemic delivery strategies to tilt the immunological balance from viral clearance to tumor elimination...
  16. ncbi request reprint Immunoglobulin M myeloma: evaluation of molecular features and cytokine expression
    Kartik Konduri
    Baylor Charles A Sammons Cancer Center, 3535 Worth Street, Dallas, TX 75246, USA
    Clin Lymphoma 5:285-9. 2005
    ..Additional studies on patients with this rare tumor may provide further insight into the pathogenesis of bone disease in plasma cell dyscrasias...
  17. ncbi request reprint Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA
    Yu An Zhang
    The Mary Crowley Medical Research Center, Dallas, Texas
    Cancer Res 66:9736-43. 2006
    ..These findings indicate that Internavec can generate a two-pronged attack on tumor cells through oncogene knockdown and viral oncolysis, resulting in a significantly enhanced antitumor outcome...

Research Grants1

  1. Oncolytic Viral Delivery of Oncogene siRNA
    Alex Tong; Fiscal Year: 2006
    ....